- Stocks
- Healthcare
- NASDAQ: POAI

Price (delayed)

$0.9

Market cap

$6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.35

Enterprise value

$3.37M

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data

The EPS has increased by 32% YoY and by 8% from the previous quarter

POAI's net income is up by 27% year-on-year and by 5% since the previous quarter

POAI's gross profit is down by 16% since the previous quarter but it is up by 4.5% year-on-year

POAI's revenue is up by 13% YoY but it is down by 11% from the previous quarter

Predictive Oncology's equity has shrunk by 72% YoY

Predictive Oncology's quick ratio has shrunk by 69% YoY

Sector: Healthcare

Industry: Medical Instruments & Supplies

Website: http://www.precisiontherapeutics.com

What are the main financial stats of POAI

Market
Valuations
Earnings

Shares outstanding

6.67M

Market cap

$6M

Enterprise value

$3.37M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.9

Price to sales (P/S)

2.4

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.93

Revenue

$1.75M

EBIT

-$14.04M

EBITDA

-$13.39M

Free cash flow

-$12.83M

Per share
Balance sheet
Liquidity

EPS

-$3.35

Free cash flow per share

-$2.75

Book value per share

$1

Revenue per share

$0.37

TBVPS

$2.22

Total assets

$10.59M

Total liabilities

$6.49M

Debt

$2.7M

Equity

$4.09M

Working capital

$2.27M

Debt to equity

0.66

Current ratio

1.49

Quick ratio

1.24

Net debt/EBITDA

0.2

Margins
Efficiency
Dividend

EBITDA margin

-765.9%

Gross margin

60.2%

Net margin

-802.9%

Operating margin

-809.5%

Return on assets

-104.4%

Return on equity

-200.1%

Return on invested capital

-358.4%

Return on capital employed

-235.2%

Return on sales

-802.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Predictive Oncology stock price performed over time

Intraday

2.39%

1 week

-1.64%

1 month

-9.13%

1 year

-73.29%

YTD

-72.64%

QTD

-13.46%

How have Predictive Oncology's revenue and profit performed over time

Revenue

$1.75M

Gross profit

$1.05M

Operating income

-$14.15M

Net income

-$14.04M

Gross margin

60.2%

Net margin

-802.9%

The company's net margin rose by 36% YoY but it fell by 6% QoQ

POAI's operating margin is up by 36% year-on-year but it is down by 6% since the previous quarter

POAI's net income is up by 27% year-on-year and by 5% since the previous quarter

POAI's operating income is up by 27% YoY and by 5% QoQ

What is Predictive Oncology's growth rate over time

What is Predictive Oncology stock price valuation

P/E

N/A

P/B

0.9

P/S

2.4

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.93

The EPS has increased by 32% YoY and by 8% from the previous quarter

Predictive Oncology's equity has shrunk by 72% YoY

The price to book (P/B) is 44% less than the last 4 quarters average of 1.6 and 40% less than the 5-year quarterly average of 1.5

The P/S is 88% lower than the 5-year quarterly average of 19.6 and 58% lower than the last 4 quarters average of 5.7

POAI's revenue is up by 13% YoY but it is down by 11% from the previous quarter

How efficient is Predictive Oncology business performance

The company's return on equity has shrunk by 119% YoY and by 31% QoQ

Predictive Oncology's ROIC has increased by 49% YoY but it has decreased by 7% from the previous quarter

The return on assets has declined by 42% year-on-year and by 13% since the previous quarter

The ROS has increased by 36% YoY but it has decreased by 6% from the previous quarter

What is POAI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for POAI.

How did Predictive Oncology financials performed over time

The company's total assets is 63% higher than its total liabilities

Predictive Oncology's quick ratio has shrunk by 69% YoY

The current ratio has dropped by 65% year-on-year but it has increased by 2.8% since the previous quarter

The company's debt is 34% lower than its equity

Predictive Oncology's equity has shrunk by 72% YoY

The company's debt fell by 9% YoY but it rose by 3.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.